Literature DB >> 15784523

Naltrexone augments the effects of nicotine replacement therapy in female smokers.

Joanne A Byars1, Kimberly Frost-Pineda, William S Jacobs, Mark S Gold.   

Abstract

BACKGROUND: There is increased recognition that gender differences may influence outcomes and may modify vulnerability to tobacco addiction, severity of course and response to different treatments. We hypothesized that naltrexone, which has been used to successfully treat opioid and alcohol dependence, when combined with nicotine replacement therapy (NRT) and psychosocial therapy (PT) may enhance smoking cessation rates in women.
METHODS: Forty-four adult female smokers meeting DSM-IV criteria for nicotine dependence with expired carbon monoxide content of > or = 15 ppm were randomly assigned in a double blind placebo controlled clinical trial of naltrexone 50 mg + NRT patch + psychosocial therapy (N + NRT + PT)(N = 12) or placebo + NRT patch + psychosocial therapy (P + N + PT)(N=12) for 12 weeks.
RESULTS: Twelve weeks of treatment was completed by 54.5%. Smoking cessation among females who completed the 12 weeks for N + NRT + PT was 91.7% (11/12) and for P + NRT + PT was 50% (6/12).
CONCLUSION: Naltrexone combined with NRT and psychosocial therapy appears to have a positive cessation effect on women and may be a new treatment option for recidivist female smokers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15784523     DOI: 10.1300/J069v24n02_05

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  16 in total

Review 1.  Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.

Authors:  Fernando Berrendero; Patricia Robledo; José Manuel Trigo; Elena Martín-García; Rafael Maldonado
Journal:  Neurosci Biobehav Rev       Date:  2010-02-16       Impact factor: 8.989

2.  Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch.

Authors:  C Neill Epperson; Benjamin Toll; Ran Wu; Zenab Amin; Kathryn A Czarkowski; Peter Jatlow; Carolyn M Mazure; Stephanie S O'Malley
Journal:  Drug Alcohol Depend       Date:  2010-06-19       Impact factor: 4.492

Review 3.  Opioid antagonists for smoking cessation.

Authors:  Sean P David; Tim Lancaster; Lindsay F Stead; A Eden Evins; Judith J Prochaska
Journal:  Cochrane Database Syst Rev       Date:  2013-06-06

Review 4.  Pharmacotherapy of dual substance abuse and dependence.

Authors:  George A Kenna; Darci M Nielsen; Patricia Mello; Alison Schiesl; Robert M Swift
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial.

Authors:  Adam Bress; Rick Kittles; Coady Wing; Stanley E Hooker; Andrea King
Journal:  Pharmacogenet Genomics       Date:  2015-06       Impact factor: 2.089

6.  Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial.

Authors:  Andrea King; Dingcai Cao; Lingjiao Zhang; Sandra Yu Rueger
Journal:  Addiction       Date:  2013-07-12       Impact factor: 6.526

7.  Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women.

Authors:  Andrea C King; Dingcai Cao; Stephanie S O'Malley; Henry R Kranzler; Xiaochen Cai; Harriet deWit; Alicia K Matthews; Ryan J Stachoviak
Journal:  J Clin Psychopharmacol       Date:  2012-10       Impact factor: 3.153

8.  Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.

Authors:  Lara A Ray; Kelly E Courtney; Dara G Ghahremani; Karen Miotto; Arthur Brody; Edythe D London
Journal:  Psychopharmacology (Berl)       Date:  2014-04-15       Impact factor: 4.530

9.  Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.

Authors:  Lara A Ray; Kelly E Courtney; Dara G Ghahremani; Karen Miotto; Arthur Brody; Edythe D London
Journal:  Am J Drug Alcohol Abuse       Date:  2014-06-20       Impact factor: 3.829

Review 10.  Addressing tobacco use disorder in smokers in early remission from alcohol dependence: the case for integrating smoking cessation services in substance use disorder treatment programs.

Authors:  David Kalman; Sun Kim; Gregory DiGirolamo; David Smelson; Douglas Ziedonis
Journal:  Clin Psychol Rev       Date:  2010-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.